Image

Development of a Scale for Cancer Patients' Willingness to Voluntarily Participate in Drug Clinical Trials

Development of a Scale for Cancer Patients' Willingness to Voluntarily Participate in Drug Clinical Trials

Recruiting
18-80 years
All
Phase N/A

Powered by AI

Overview

The goal of this observational study is to develop a scale for cancer patients' willingness to voluntarily participate in drug clinical trials and evaluate its reliability and validity.

Description

Inclusion Criteria:

  1. Age 18-80 years old (including boundary values).
  2. Tumor patients with clear diagnosis.
  3. Whether they finally sign the informed consent form of one drug clinical trial or not, and whether they are finally enrolled in one drug clinical trial or not, patients who have undergone the informed consent process of drug clinical trials conducted by clinicians can be enrolled in this study.
  4. Volunteer to participate in this study and sign an informed consent form.

Exclusion Criteria:

  1. Patients with unclear consciousness.
  2. Patients who are unable to correctly understand and answer questions.
  3. Vulnerable subjects include: students and subordinates of researchers, military personnel, prisoners, patients with incurable diseases, patients in critical situations, those admitted to welfare institutions, homeless individuals, minors, and those who are unable to provide informed consent.

Eligibility

Inclusion Criteria:

  1. Age 18-80 years old (including boundary values).
  2. Tumor patients with clear diagnosis.
  3. Whether they finally sign the informed consent form of one drug clinical trial or not, and whether they are finally enrolled in one drug clinical trial or not, patients who have undergone the informed consent process of drug clinical trials conducted by clinicians can be enrolled in this study.
  4. Volunteer to participate in this study and sign an informed consent form.

Exclusion Criteria:

  1. Patients with unclear consciousness.
  2. Patients who are unable to correctly understand and answer questions.
  3. Vulnerable subjects include: students and subordinates of researchers, military personnel, prisoners, patients with incurable diseases, patients in critical situations, those admitted to welfare institutions, homeless individuals, minors, and those who are unable to provide informed consent.

Study details
    Cancer

NCT06120335

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

29 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.